CarThera

Focus: CarThera is a neurology-focused biotech company specializing in brain therapy devices, operating from Lyon, France since 2010. The company is in Series B stage, indicating early-to-mid development phase with significant growth ahead.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About CarThera

AI assessmentNot Hiring

No open roles listed right now. Follow CarThera to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SonoCloud®

Malignant Brain Tumor

Phase 1

Clinical Trials (1)

NCT05293197Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

Phase 1

Help build intelligence for CarThera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape a focused neurology device company at a critical inflection point (Series B financing stage)
European biotech with specialized focus on brain therapy devices offers differentiated technical expertise and niche market positioning
Early-stage company culture with potential for significant career acceleration and equity upside if successful

Watch Out For

Zero active clinical trials reported and no disclosed pipeline programs suggest early-stage or stalled development pipeline
Currently zero open job positions indicates company is not actively hiring, limiting near-term employment opportunities
Pre-revenue status with limited financial disclosure creates uncertainty around cash runway, burn rate, and long-term viability

Generated by Claude from CarThera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sonication for opening of blood-brain barrier

Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT04528680Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Phase 1/2

SonoCloud-9

Glioblastoma, Adult

Phase 1/2

Clinical Trials (1)

NCT03744026Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

Phase 1/2